Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli.

Currently, no specific therapeutics are available for foodborne Shiga toxin-producing Escherichia coli (STEC) infections that cause severe gastroenteritis and life-threatening complications of hemolytic uremic syndrome (HUS). As STEC attachment to intestinal epithelium might increase the host absorption of Shiga toxins and severity of the disease, we were inspired to develop a bispecific neutralizer capable of blocking its Shiga toxin and adhesin intimin simultaneously. Two nanobodies against the B subunit of Shiga toxin 2 (Stx2B) and the C terminus of Intimin (IntC280) were genetically fused together as the bispecific neutralizer, and it can be efficiently produced in a conventional E. coli expression system. We demonstrated that each of the nanobody modules in the bispecific format showed increased antigen binding capability and was able to functionally neutralize the binding of Stx2B or IntC280 to the respective host receptors even in the presence of the two virulence factors together. Moreover, the bispecific neutralizer was relatively stable to harsh storage conditions and gastrointestinal pH extremes. Taking into account its easy and economical production and superior pharmaceutical properties, we believe that a nanobody-based bispecific neutralizer would be more favorable and practical to be developed as a therapeutic to fight STEC in the developing world.

Citation

Zhongkai Lu, Zhicheng Liu, Xia Li, Xinfang Qin, Haofei Hong, Zhifang Zhou, Roland J Pieters, Jie Shi, Zhimeng Wu. Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli. ACS infectious diseases. 2022 Feb 11;8(2):321-329

Mesh Tags

Substances

PMID: 35015516

search → result